Market research
SPARC.NSE Sun Pharma Advanced Research Company Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 64B
- P/E ratio
- 4.02
- Analyst target
- 2000
- Dividend yield
- Not available
- Beta
- 0.65
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE232I01014
- Market cap
- 64B
- P/E ratio
- 4.02
- Analyst target
- 2000
- Dividend yield
- Not available
- Beta
- 0.65
About
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SPARC.NSE discussion.
5 years, 5 months ago
Sun Pharma Advanced Research Company Limited is currently in a long term uptrend where the price is trading 31.6% above its 200 day moving average.
From a valuation standpoint, the stock is 259.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 17.2.
Sun Pharma Advanced Research Company Limited's total revenue rose by 11.3% to $218M since the same quarter in the previous year.
Its net income has dropped by 21.8% to $-676M since the same quarter in the previous year.
Finally, its free cash flow grew by 89.2% to $-157M since the same quarter in the previous year.
Based on the above factors, Sun Pharma Advanced Research Company Limited gets an overall score of 3/5.